Lclusig (Ponatinib) 45mg Online

$10,500.00$29,250.00

Iclusig (ponatinib) is a cancer medicine that interferes with the growth of some cancer cells. Iclusig is used in adults to treat a type of blood cancer called chronic myeloid leukemia (CML), or Philadelphia chromosome positive acute lymphoblastic leukemia (ALL).
BRAND: Ariad

Clear
SKU: N/A Category:

Description

Lclusig (Ponatinib) 45mg Online

Iclusig (ponatinib) is a cancer medicine that interferes with the growth of some cancer cells. Iclusig is used in adults to treat a type of blood cancer called chronic myeloid leukemia (CML), or Philadelphia chromosome-positive acute lymphoblastic leukemia (ALL). Iclusig is usually given after other similar medications have been tried without success.
BRAND: Ariad

Iclusig (ponatinib) is a protein kinase inhibitor that is licensed for the treatment of chronic myeloid leukaemia (CML) and Philadelphia chromosome-positive acute lymphoblastic leukaemia (Ph+ ALL) when certain other protein kinase inhibitors are unsuitable and in patients with the T315I resistance mutation. In the analysis at 12 months (median 14.5 months), there were clinically meaningful responses to ponatinib in all stages of leukaemia. Overall, 54% of patients with chronic phase CML and 70% of patients with the T315I mutation achieved a major cytogenetic response. Among patients with advanced CML, 58% of those with accelerated phase disease and 31% of those with blast phase disease achieved a major haematologic response. The Ph+ ALL group showed a major haematologic response rate of 41%.1

The most commonly reported adverse effects were blood dyscrasias (particularly thrombocytopenia) and skin disorders.
Ponatinib HCl is an off-white to yellow powder with pKa of 2.77 and 7.8. The solubility of ponatinib in pH 1.7, 2.7, and 7.5 buffers is 7790 mcg/ml, 3.44 mcg/ml, and 0.16 mcg/ml, respectively, indicating a decrease in solubility with increasing pH. Iclusig tablets are available as white, round, film-coated tablets for oral administration. Each tablet contains ponatinib hydrochloride equivalent to 15, 30, or 45 mg ponatinib with the following inactive ingredients: lactose monohydrate, microcrystalline cellulose, sodium starch glycolate (type B), colloidal silicon dioxide, magnesium stearate, and a tablet coating. You may need to have a negative pregnancy test before starting this treatment.

Ponatinib may harm an unborn baby. Use effective birth control to prevent pregnancy while you are using this medicine and for at least 3 weeks after your last dose. This medicine may affect fertility (ability to have children) in women. However, it is important to use birth control to prevent pregnancy because Iclusig can harm an unborn baby.